Skip to main content
Premium Trial:

Request an Annual Quote

Cenix to Help Regulus Develop Targets for miRNA-Based Drugs

NEW YORK (GenomeWeb News) – Cenix BioScience said today that it has agreed to help Regulus Therapeutics develop its miRNA modulators for immunology and inflammation therapeutics. 
Under the research agreement, Cenix said it will use multi-parametric assays to screen Regulus’ libraries of synthetic miRNA modulators for novel molecules that could be used to develop new therapeutics. Specifically, Cenix said that it will apply its small RNA-based gene silencing technology with high-content phenotypic analyses in cultured human cells.
Regulus is a California-based company that was founded in 2007 as a joint effort between Alnylam Pharmaceuticals and Isis Pharmaceuticals.
Cenix offers research and consulting services using human and rodent cell models to discover, validate, and analyze new drug targets for a variety of diseases including atherosclerosis, diabetes, obesity, malaria, and others.

Financial terms of the agreement were not released.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.